Could a Vitamin-Like pill stop prediabetes from becoming diabetes?
NCT ID NCT07286747
First seen Jan 05, 2026 · Last updated Jun 24, 2026 · Updated 25 times
Summary
This phase II trial tests whether a special form of nicotinic acid (a B vitamin) can reverse prediabetes and prevent type 2 diabetes. About 390 adults with prediabetes will take either a low or high dose of the drug or a placebo daily for 26 weeks, along with lifestyle advice. The goal is to see if the drug can bring blood sugar levels back to a healthy range.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREDIABETES (INSULIN RESISTANCE, IMPAIRED GLUCOSE TOLERANCE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Medical Center Schleswig-Holstein, Campus Kiel
RECRUITINGKiel, 24105, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Leipzig Medical Center
RECRUITINGLeipzig, 04103, Germany
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
controlled-ileal-release nicotinic acid (CIR-NA)
What this could lead to
If it works, this could offer a new way to prevent prediabetes from turning into type 2 diabetes, potentially reducing the need for lifelong medication.
What could go wrong
This is a phase II trial, so it's still early. The drug may not work better than placebo, and side effects like flushing or stomach issues are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.